What question did this study set out to answer?

To evaluate the effects of chemotherapy cycles and anthracycline use on outcomes in pediatric low-risk AML patients.

December 8, 2025BloodOpen Access

Optimized treatment for pediatric patients with low-risk Acute Myeloid Leukemia: A report from the Children's oncology group study AAML1831

View Full Paper

Ask AI

Bookmark

Authors

Phase 3 trial shows 5 cycles of chemotherapy improves outcomes in pediatric AML, indicating potential therapy reduction.

To evaluate the effects of chemotherapy cycles and anthracycline use on outcomes in pediatric low-risk AML patients.
Retrospective application of risk stratification criteria from AAML1831 to previous trials AAML0531 and AAML1031.
Comparison of 2-year relapse rate, disease-free survival, and overall survival across risk groups and treatment regimens.
Multivariable analysis to assess the importance of the 5th treatment cycle.
LR2 patients treated with 5 cycles had a lower 2-year relapse rate than those on 4 cycles (24% vs 44%).
For LR1 patients, no significant difference in relapse rate or disease-free survival was observed between 4 cycles on AAML1831 and 5 cycles on AAML0531.
Omission of the 5th cycle in LR1 did not reduce overall survival and allowed for a reduction in anthracycline exposure.

Aplenc et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark